Abstract Recent studies have shown that p53 contributes to poor survival during immune checkpoint blockade (ICB) therapy. Lung cancer patients with p53 mutations have significantly improved response rates to PD-1 ICB therapy. While previous studies have shown that tumor-derived IL-33 is required for...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!